Prana gives update on AD candidate
Melbourne, Australia-based Prana Biotechnology's co-founder, Rudolph Tanzi, updated a US Special Committee regarding the firm's lead compound PBT2, which recently concluded a Phase IIa trial in early Alzheimer's disease.
Prana says the trial showed safety and tolerability, as well as significant reductions in Abeta 42 and improvement in Executive Function performance in cognitive tests. Prana will be presenting this data at the International Conference on Alzheimer's Disease in Chicago at the end of the month.
Dr Tanzi said that, "unlike other approaches, Prana's PBT2 appears to neutralize the neurotoxicity of Abeta and facilitates its clearance from the brain. I testified to the US Senate that therapies targeted against the amyloid beta protein offer the best chance at slowing down the progression of Alzheimer's disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze